Tuesday, January 6, 2009 - 9:16PM EST

Review Articles

21. Comparison of low-density lipoprotein cholesterol reduction after switching patients on other statins to rosuvastatin or simvastatin in a real-world clinical practice setting.

Author
Fox KM; Gandhi SK; Ohsfeldt RL; Davidson MH;
Institution
kathyfox@comcast.net
Journal
Am J Manag Care. 2007 Dec;13 Suppl 10:S270-5.
Abstract URL
Click here to view abstract

22. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths.

Author
Lewington S; Whitlock G; Clarke R; Sherliker P; Emberson J; Halsey J; Qizilbash N; Peto R; Collins R;
Institution
CTSU, University of Oxford, Oxford OX3 7LF, UK.
Journal
Lancet. 2007 Dec 1;370(9602):1829-39.
Abstract URL
Click here to view abstract

23. Increasing high-density lipoprotein cholesterol, inhibition of cholesteryl ester transfer protein, and heart disease risk reduction.

Author
Schaefer EJ; Asztalos BF;
Institution
Cardiovascular Research and Lipid Metabolism Laboratories, Tufts University, Boston, Massachusetts 02111, USA. ernst.schaefer@tufts.edu
Journal
Am J Cardiol. 2007 Dec 3;100(11 A):n25-31.
Abstract URL
Click here to view abstract

24. Measuring cholesterol levels.

Author
Pottle A;
Institution
Harefield Hospital, Harefield, Middlesex. a.pottle@rbht.nhs.uk
Journal
Nurs Stand. 2007 Jul 25-31;21(46):42-7.
Abstract URL
Click here to view abstract

25. ISIS 301012 gene therapy for hypercholesterolemia: sense, antisense, or nonsense?

Author
Ito MK;
Institution
College of Pharmacy, Oregon State University/Oregon Health & Science University, Portland Campus at OHSU, 3303 SW Bond Ave., Portland, OR 97239, USA. itom@ohsu.edu
Journal
Ann Pharmacother. 2007 Oct;41(10):1669-78. Epub 2007 Sep 11.
Abstract URL
Click here to view abstract

26. Optimal low-density lipoprotein cholesterol lowering--morning versus evening statin administration.

Author
Plakogiannis R; Cohen H;
Institution
Arnold & Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, NY 11201, USA. roda.plakogiannis@liu.edu
Journal
Ann Pharmacother. 2007 Jan;41(1):106-10. Epub 2007 Jan 2.
Abstract URL
Click here to view abstract

27. Effects of statins, fibrates, rosuvastatin, and ezetimibe beyond cholesterol: the modulation of LDL size and subclasses in high-risk patients.

Author
Rizzo M; Rini GB; Berneis K;
Institution
Department of Clinical Medicine and Emerging Diseases, University of Palermo, Italy. mrizzo@unipa.it
Journal
Adv Ther. 2007 May-Jun;24(3):575-82.
Abstract URL
Click here to view abstract

28. Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials.

Author
Alsheikh-Ali AA; Maddukuri PV; Han H; Karas RH;
Institution
Molecular Cardiology Research Institute and Division of Cardiology, Department of Medicine, Tufts-New England Medical Center and Tufts University School of Medicine, Boston, Massachusetts 02111, USA.
Journal
J Am Coll Cardiol. 2007 Jul 31;50(5):409-18. Epub 2007 Jul 16.
Abstract URL
Click here to view abstract

29. Drug evaluation: ISIS-301012, an antisense oligonucleotide for the treatment of hypercholesterolemia.

Author
Burnett JR;
Institution
Royal Perth Hospital, Department of Core Clinical Pathology and Biochemistry, PathWest Laboratory Medicine WA, Wellington Street, GPO Box X2213, Perth, WA 6847, Australia. john.burnett@health.wa.gov.au
Journal
Curr Opin Mol Ther. 2006 Oct;8(5):461-7.
Abstract URL
Click here to view abstract

30. Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials.

Author
Thavendiranathan P; Bagai A; Brookhart MA; Choudhry NK;
Institution
Department of Medicine, University of Toronto, Toronto, Ontario.
Journal
Arch Intern Med. 2006 Nov 27;166(21):2307-13.
Abstract URL
Click here to view abstract
Pages: 1 2 3 4 5 6